Michael Mauro, MD

Michael J. Mauro, MD, discusses the risks of disease progression in myelofibrosis.

Michael J. Mauro, MD, discusses considerations for early treatment initiation in myelofibrosis.

Michael J. Mauro, MD, discusses managing symptom burden in patients with myelofibrosis.

Michael Mauro, MD, hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, discusses treatment discontinuation for patients with chronic myeloid leukemia.